Skip to main content
FLYW $18.81 +3.13%
FLYW logo

FLYW · Flywire Corp

Track FLYW — free
$18.81 +0.57 (+3.13%) At close · Aug 14
Market Cap
$2.29B
Shares
121.67M
All earnings calls

Earnings call · FY2026 Q1

Flywire Corp Q1 FY2026 Earnings Call

Flywire Corp Q1 FY2026 Earnings Call

Concluded May 5, 2026
May 5, 2026 57 turns
Period
FY2026 Q1
Runtime
Sources
3 artifacts

Executive readout · one minute

What matters this quarter

Flywire delivered a first-quarter beat on the top and bottom line with broad-based outperformance across education, travel, healthcare and B2B, and raised its full-year outlook by 150 bps on payment processing contribution to 3%–4%. Management reaffirmed a path to 24%–25% Adjusted EBITDA margins exiting the year and highlighted accelerating deal activity, AI-driven operating efficiencies and continued progress on Cleveland Clinic and Sertifi cross-sell ramps.

Cross-vertical growth and outperformance 63 Sertifi hospitality cross-sell 28 Payment processing ramps (Cleveland Clinic, B2B) 22 Integrations and partnerships moat 18 Platform scale and network effects 16 Land-and-expand go-to-market 9

Management tone

Confident

Net tone +82 · low hedging

Grounding quotes
  • “It was a great quarter with significant growth and a beat on both the top and bottom line, with broad-based outperformance across education, travel, healthcare and B2B.”
  • “We are executing against our multiyear strategy to deliver $1 billion in revenue with impressive financial metrics, and I want to spend a moment on why those metrics keep improving.”
  • “Our momentum is yet another proof point. When clients stay, expand and refer others to Flywire, the market is telling you clearly our model works.”
  • “I feel good about the sort of mid-30s for the year with higher leaning into the second half.”

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $188.11M +41% YoY
Diluted EPS $0.10
Net income $12.52M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q1 results were a top- and bottom-line beat with broad-based outperformance across education, travel, healthcare and B2B.
  • Raised full-year payment processing contribution guidance from 2% to 3%–4%, driven by Cleveland Clinic and B2B invoice ramps.
  • Expect incremental margins to accelerate to the mid-30s for the year and 24%–25% Adjusted EBITDA margins exiting the year.
  • Cleveland Clinic software module remains on track for Q2 launch, described as higher-margin revenue supporting gross margins.
  • Management cited faster time to signature, larger deal sizes and deal counts in a ~200-deal range per quarter, reflecting strong land-and-expand execution.
  • AI-driven automation has auto-resolved ~40% of customer inquiries and reduced support handling time/cost per contact by ~30%, supporting operating leverage.

Risks & pressure points

  • Cleveland Clinic and B2B invoice ramp benefits are expected to lap in the second half, meaning easier comparisons will fade.
  • Management explicitly flagged Q2 will carry elevated investment spend before second-half margin acceleration materializes.
  • Repurchases under the previously announced ASR program are subject to market conditions and may be discontinued, accelerated, suspended or delayed.
  • Cross-border and education volumes remain exposed to U.S. policy and immigration/visa changes, tariffs and global recession risks flagged as risk factors.
  • Management cited rising geopolitical risks, including hostilities involving Ukraine, Israel, Hamas and Iran, as factors that could affect results.

Key moments

Jump directly to management's words in the synchronized transcript.

“It was a great quarter with significant growth and a beat on both the top and bottom line, with broad-based outperformance across education, travel, healthcare and B2B. We are building for scale while driving efficiencies into our operations.” Michael Massaro, CEO
“We are executing against our multiyear strategy to deliver $1 billion in revenue with impressive financial metrics, and I want to spend a moment on why those metrics keep improving.” Michael Massaro, CEO

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
FX-neutral revenue growth
full year 2026
18% – 24%
Adjusted EBITDA margin expansion
full year 2026
175% – 375%
Free cash flow conversion of adjusted EBITDA
full year 2026
70% – 75%

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Transactions$155.21M +43.1% YoY
Platform and Other Revenues$32.91M +31.8% YoY

Capital returned

Buybacks
$10.03M
Shares repurchased
10,031
Full-screen source Call document